Találati lista | Tudóstér

001-es BibID:	BIBFORM080686
035-os BibID:	(Scopus)85065427841
Első szerző:	Bereczky Zsuzsanna (orvosi laboratóriumi diagnosztika szakorvos)
Cím:	Inherited thrombophilia and the risk of myocardial infarction : current evidence and uncertainties / Zsuzsanna Bereczky, László Balogh, Zsuzsa Bagoly
Dátum:	2019
ISSN:	0022-9032
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Kardiologia Polska. - 77 : 4 (2019), p. 419-429. -
További szerzők:	Balogh László Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:	NKFIH FK128582 egyéb NKFIH K120042 egyéb NKFIH K116228 egyéb GINOP-2.3.2.-15-2016-00043 egyéb GINOP-2.3.2.-15-2016-00039 egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM082985
035-os BibID:	(PMID)31808421
Első szerző:	Lóczi Linda
Cím:	Antiphospholipid syndrome and the risk of myocardial infarction : current evidence and uncertainties / Linda Lóczi, János Kappelmayer, Tünde Tarr, Zsuzsa Bagoly
Dátum:	2020
ISSN:	0022-9032
Megjegyzések:	Antiphospholipid syndrome (APS) encompasses a wide spectrum of disease manifestations that may prevail in the form of venous or arterial thrombosis or lead to pregnancy complications in the presence of persisting antiphospholipid antibodies (aPL). Unlike in the case of congenital thrombophilias, in which venous thromboses are more likely to occur as compared with arterial events, aPL may cause thrombosis in both types of vascular systems. Arterial thrombosis in APS is fairly common and often involve coronary or cerebral arteries leading to myocardial infarction (MI) or stroke. In this review, we summarize the complex pathomechanisms leading to aPL?associated thrombosis and list challenges during the laboratory detection of these antibodies. Specific features of MI in patients with APS are summarized based on a comprehensive literature search of available case reports. Preventive and treatment strategies are discussed based on the current recommendations and most recent evidence. We conclude that the risk of MI in patients with APS is considerable and MI may be the first manifestation of the disease. MI in APS shows specific clinical features including relatively young age at presentation, no sex dominance, often normal coronaries without the sign of atherosclerosis, high risk of recurrent thrombotic events. Treatment of acute MI in patients with APS is often challenging and adverse events, including stent thrombosis, are more frequent as compared with patients without APS. Preventive strategies in APS should be personalized and include strict management of additional cardiovascular risk factors and long?term anticoagulation with vitamin K antagonists. Current evidence does not support the use of direct oral anticoagulants in the management of patients with APS with arterial thrombosis due to the high risk of recurrent events.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Kardiologia Polska. - 78 : 1 (2020), p. 6-14. -
További szerzők:	Kappelmayer János (1960-) (laboratóriumi szakorvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:	FK128582 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM017813
Első szerző:	Márk László (belgyógyász, kardiológus)
Cím:	Cytochrome P450 2C9 polymorphism and acenocoumarol therapy / Laszlo Mark, Janos Marki-Zay, Lajos Fodor, Ildiko Hajdara, György Paragh, Andras Katona
Dátum:	2006
Megjegyzések:	BACKGROUND: Oral anticoagulants, in Hungary acenocoumarol being the one exclusively used, have a low therapeutic index and a high bleeding complication rate. The cytochrome P450 2C9 enzyme plays an important role in their metabolism. AIM: To investigate the influence of CYP2C9 polymorphism on the occurrence of bleeding complications related to acenocoumarol therapy. METHODS: Genotyping of 421 patients (183 men and 238 women, mean age 66.2+/-11.8 years), who had been taking acenocoumarol for at least 6 months, was performed. Based on patient history and laboratory data, the correlations between genotype and acenocoumarol dose and bleeding complications were retrospectively analysed. RESULTS: In 145 patients bearing alleles with reduced activity (CYP2C92 and/or 3), the optimal dose of acenocoumarol was significantly (p<0.001) lower than in patients with the wild type allele (2.12+/-0.96 mg/day and 2.90+/-1.46 mg/day, respectively). In comparison with wild type allele patients, the mean daily acenocoumarol dose was lower in the CYP2C92 group, and the lowest in 3 bearers. Although the occurrence of minor bleeding complications in patients with the variant allele was significantly (p <0.005) higher (OR=1.99 [CI: 1.20-3.33]) than in other patients, there was no difference in major bleeding complications. CONCLUSIONS: Patients bearing CYP2C9 alleles with reduced enzymatic activity have a lower acenocoumarol requirement. In patients with CYP2C92 and 3 alleles the frequency of minor bleeding complications and the occurrence of high INR values were significantly higher, but there was no difference in the rate of major bleedings.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Kardiologia polska 64 : 4 (2006), p. 397-402. -
További szerzők:	Marki-Zay János Fodor Lajos (orvos) Hajdara Ildikó Paragh György (1953-) (belgyógyász) Katona András
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: